Phase 2 Pulmonary Hypertension Trial, Recruiting NCT04898114 Sponsor: Sohag University Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 2 Pulmonary Hypertension Trial, Recruiting

NCT04898114
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The baby was born at 36 weeks of pregnancy or later (not very premature).
  • The baby weighs between 2.5 kg and 4 kg at birth.
  • The baby is between 6 and 72 hours old at the time of joining the trial.
  • The baby has been diagnosed with a specific lung blood pressure condition called PPHN, confirmed by a heart ultrasound scan.
  • The baby's oxygen levels are severely low, measured by a specific test (called an oxygenation index) showing a reading above 30 on two separate checks at least 15 minutes apart.
  • The baby is currently on a breathing machine (mechanical ventilator).

Who may not be able to join:

  • The parent or guardian has not given their permission (informed consent) for the baby to take part.
  • The baby's mother received a medicine called magnesium sulfate within 48 hours before giving birth.
  • The baby has a heart defect, apart from two common and minor ones that many newborns have (a small opening between heart vessels that often closes naturally).
  • The baby has a major birth defect, including problems with the diaphragm or underdeveloped lungs.
  • The baby has already needed emergency heart and lung resuscitation.
  • The baby has very low blood pressure that has not responded to fluids or medicines to support the heart.
  • The baby has reduced or impaired kidney function.
  • The baby has already been given medicines to improve blood flow in the lungs.
  • The baby has stomach or intestinal problems, including bleeding in the digestive tract.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Elsayed Abdelkreem, MD, PhD, Sohag University

Phone: 00201114232126

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
2 June 2021
Est. completion
30 April 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

Change in Oxygenation index (OI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov